Rigel hit with another trial setback as lead drug fostamatinib fails PhII
Rigel’s roller coaster ride of advances and setbacks continued this morning with the news that its drug fostamatinib failed a mid-stage study in IgA nephropathy, flunking the primary endpoint.
Investigators at the biotech $RIGL have been steering through a series of close hits and misses in the clinic, sending its shares yo-yoing over the past two years. The drug did not produce a significant mean change in proteinuria compared to a placebo.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
